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SUMMARY 
The genes encoding ABC transporters occupy 2.5% of the genome of Mycobacterium 
tuberculosis . However, none of these putative ABC transporters has been characterized so far. 
We describe the development of expression systems for simultaneous expression of the ATP-
binding protein DrrA and the membrane integral protein DrrB which together behave as a 
functional doxorubicin efflux pump. Doxorubicin uptake in Escherichia coli or Mycobacterium 
smegmatis expressing  DrrAB was inhibited by reserpine, an   inhibitor of ABC transporters. The  
localization of DrrA to the membrane depended on the simultaneous expression of DrrB. ATP 
binding was positively regulated by doxorubicin and daunorubicin. At the same time, DrrB 
appeared to be sensitive to proteolysis when expressed alone in the absence of DrrA. 
Simultaneous expression of the  two polypeptides was essential in order to obtain a functional 
doxorubicin efflux pump. Expression of DrrAB in E. coli conferred  8-fold increased resistance to 
ethidium bromide, a cationic compound. 2’,7’-bis-(2-carboxyethyl)-5(-and 6)-carboxyfluorescein 
(BCECF), a neutral compound also behaved as a substrate of the  reconstituted efflux pump. 
When  expressed in M.  smegmatis, DrrAB conferred resistance to  a number of clinically 
relevant,  structurally unrelated antibiotics. The resistant phenotype could be reversed by 
verapamil and reserpine, two potent inhibitors of ABC transporters. 
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Mycobacterium tuberculosis accounts for the largest number of deaths caused by a single human 
pathogen with predictions of an excess of 80 million new cases and 20 million deaths in the 
coming decade. The appearance of  drug-resistant strains of M. tuberculosis and the HIV 
pandemic  have exacerbated this situation. Effective treatment of tuberculosis infections requires 
the identification of new drugs, drug targets and drug resistance factors. The ABC (ATP-Binding 
Cassette) transporters [1], constitute a large superfamily of  multi-subunit permeases that 
transport  diverse molecules (ions, amino acids, peptides, drugs, antibiotics, lipids,  
polysaccharides, proteins etc.) at the expense of ATP [2, 3]. The genes encoding the ABC 
transporters occupy about 2.5% of the genome of M. tuberculosis. [4].  At least 37 complete and 
incomplete ABC transporters have been identified in M. tuberculosis  based on the  structural 
similarities of the typical subunits of ABC transporters present in all living organisms.  
Knowledge of these  M.tuberculosis ABC transporters  is necessary both for understanding their 
involvement in the development of multidrug resistance in M. tuberculosis as well as in the 
export of the unique antigenic cell surface components of this organism, such as the phthiocerol 
mycocerosates and lipoarabinomannan. 
The prototype eukaryotic ABC transporter is the P-glycoprotein [P-gp] [5]. The 170 kDa P-
glycoprotein is characterized by two membrane integral domains with six membrane-spanning 
helices each connected with two ATP hydrolyzing domains and the presence of the “Walker sites 
A and B” [6] in the primary structure of the ATP-hydrolyzing domains, which by analogy with 
ATP-and GTP-binding proteins, bind nucleotides [7, 8]. The doxorubicin resistance operon, first 
identified in Streptomyces peucetuis [9] bears analogy to the eukaryotic  P-glycoprotein. Two 
translationally coupled open reading frames drrA and drrB encode an ABC type transporter, with 
drrA encoding the nucleotide-binding domain and drrB encoding the membrane integral 
component [10]. A monomer of DrrA and DrrB form a molecule about half the size of Pgp. The 
likely stoichiometry of the functional transporter is DrrA2 B2 [10]. By analogy to S. peucetius, the 
completed Mycobacterium tuberculosis genome [11] also contains a doxorubicin resistance 
operon drr. In addition, the drr operon has  been identified in the  genomes of M. leprae and  M. 
avium. As powerful techniques of molecular biology have become available, the drr operon has 
assumed particular significance in relation to its implications in virulence of M. tuberculosis. The 
biosynthesis of phthiocerol dimycocerosates (DIM) involves several genes [12]. The genes pps A-
E, encode a type I modular polyketide synthase responsible for the synthesis of phthiocerol and 
phenolphthiocerol. Another gene, mas encodes an iterative  type I polyketide synthase that 
produces mycocerosic  acid. The gene fadD28 is probably involved in the release and transfer of 
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mycocerosic acid from Mas onto the diols. These 7 genes are clustered on a 50 kb fragment of the 
chromosome containing among other genes, the ORFs of the drr operon and  mmpl7 encoding 
polypeptides similar to ABC transporters. Signature-tagged transposon mutagenesis has shown 
that transposon insertions in the drr operon  or mmpl7 lead to a strong growth defect  
M.tuberculosis  in lungs of intravenously infected mice [13, 14] and in export of DIM to the cell 
surface [15].  
The biochemical characterization of the Drr transporter assumes obvious importance in the light 
of these recent observations. Its association with virulence suggests that it presents an attractive 
drug target, which if inactivated, will probably disable the pathogen in terms of its ability to 
export complex molecules such as DIM, a surface-exposed antigenic lipid present in seven 
pathogenic species of mycobacteria [16], to the cell surface. In addition, the likely importance of 
the drr operon in multidrug resistance deserves evaluation. The biochemical characterization of 
the drr operon was undertaken before most of these recent observations came to light, envisaging 
its likely importance in multidrug resistance of M. tuberculosis. The goal was to develop 
expression systems expressing a functional DrrAB transporter in order to evaluate the role of the 
transporter in drug resistance as well as to exploit the expression systems in further 
characterization of the transporter in relation to the roles of the conserved domains in transport 
function. 
EXPERIMENTAL PROCEDURES 
Materials- [14C]Doxorubicin and the Thermosequenase cycle sequencing kit were purchased from 
Amersham Pharmacia Biotech, Buckinghamshire, U.K. Restriction enzymes  and antibiotics were 
purchased from Life Technologies, Gaithersberg, Maryland, U.S.A, [a-32P]ATP was purchased 
from NEN Life Sciences, Boston, U.S.A., and 2’,7’-bis-(2-carboxyethyl)-5(-and 6)-
carboxyfluorescein acetomethoxyl ester (BCECF-AM) was a product of Molecular Probes, 
Eugene, Oregon, U.S.A.  Doxorubicin, daunorubicin, ethidium bromide, reserpine, verapamil,  
chloramphenicol, tetracycline, erythromycin, ethambutol, rifampicin,  norfloxacin, streptomycin 
and  puromycin were products of Sigma Chemicals, St. Louis, Missouri, U.S.A. All other 
reagents were of analytical grade. 
Strains- Cloning was performed in E. coli DH5a. E. coli LMG194 [Invitrogen] and E. coli 
BL21(DE3) [Novagen] were used for protein expression. M. smegmatis mc2155 has been 
described by Snapper et al. [17]. 
Amplification and cloning of drrAB from cosmid  MTCY19H9-The drrAB operon was amplified 
from the cosmid MTCY19H9 (a kind gift from Stewart Cole, Institut Pasteur, Paris) using the 
primer pair: sense: 5’CGG GGT ACC ATA TGC GCA ACG ACG ACA TGGC 3’ and  
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antisense 5’CCC GAA TTC GTC GTG ATC ATG GGCC GCC TAG 3’ with asymmetric KpnI 
and EcoRI sites (underlined) in the sense and antisense primers respectively.  The PCR product 
was digested with KpnI and EcoRI, cloned in the vector pUC19 between the KpnI and EcoRI 
sites to generate the plasmid pCKB101, and sequenced on both strands . The sequenced  drrAB 
gene was excised from pUC19 and cloned between the NdeI (indicated in bold) and EcoRI sites 
of the expression vector pET 28a+ (Novagen) to give the plasmid pCKB102.  
Cloning of the drrA gene- The drrA gene was amplified from plasmid pCKB101  using the 
following primer pair: 5’CGG GGT ACC ATA TGC GCA ACG ACG ACA TGGC3’ (sense) 
and 5’ATA GAA TTC ATC GCG CGG ACC CCG ACA CCA G3’ (antisense)  with asymmetric 
BglII and EcoRI sites,   and cloned in the vector pK18 [18] between the BglII and  EcoRI sites to 
generate the plasmid pCKB104. pCKB104 was sequenced and the drrA gene was excised and 
cloned between the NdeI and EcoRI sites of pET28a+ to give pCKB105.  
Cloning of the drrB gene- The drrB gene was amplified from plasmid pCKB101  using the 
following primer pair: 5’ ATA GGT ACC ATA TGA GCG GCC CGG CCA TAG ATG CG 3’ 
(sense) and  5’CCC GAA TTC GTC GTG ATC ATG GGCC GCC TAG 3’ (antisense)  with 
asymmetric BglII and EcoRI sites,   cloned in the vector pK18 to give pCKB107 and sequenced 
The drrB gene was excised and cloned between the NdeI and EcoRI sites of pET28a+ to give 
pCKB108, as well as between the BglII and EcoRI sites of  pBAD-HisA to give pCKB109.  
Construction of an artificial operon- pCKB108 was digested with NcoI and NdeI to eliminate a 
58 bp fragment. This was replaced by oligonucleotides   5’CATGGCTGGTACCGGGGT CAA 
GGA GAT AAC A 3’ and its reverse complement strand, with overhangs of CATG at the 5’end 
and AT at the 3’ end to complement NcoI and NdeI respectively. The resulting plasmid  termed   
pCKB110, contained a  KpnI site (underlined) and a Shine-Delgarno (SD) sequence (AGGA) . 
The drrA gene was amplified from pCKB105 using the primers: sense 5’GAA GAT CTC ATA 
TGC GCA ACG ACG ACA TGG C 3’ and antisense 5’GGAATT CGG TAC CAG ATG GGT 
CAG AGA CTC GGT 3’ with asymmetric NdeI and EcoRI sites and cloned between the NdeI 
and EcoRI sites  of pET28a+ to give pCKB111.  Plasmid pCKB110 was digested with KpnI and 
EcoRI and the fragment containing the drrB gene with the upstream SD sequence was cloned 
between the KpnI and EcoRI sites of pCKB111 to give pCKB112. pCKB112 therefore contains 
the translationally coupled drrAB genes, with the artificial ribosome binding site AGGA upstream 
of the drrB gene,  under the control of the T7 promoter. The following cloning steps were 
performed in order to introduce the myc epitope at the C-terminal end of DrrB.  Using pCKB112 
as template, the drrA and drrB genes were amplified using the primer pair 5’ GAAGATCTCAT 
ATG CGC AAC GAC GAC ATG GC3’ (sense) [primer DrrA-His] and 5’AAAAAGCTT TGG 
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CCG CCT AGC CAA AAC GTT TTG GCT AGG CGG CCA3’ (antisense) [BglII and HindIII 
sites in the sense and antisense primers underlined] and cloned between the BglII and HindIII 
sites of pBAD myc HisA to give plasmid pCKB113 carrying a translational fusion of the myc 
epitope to the C-terminal end of DrrB. Primer DrrA-His was used as the sense primer paired with 
the antisense primer: 5’ATG GAATTC TCA GTC GAC GGC GCT ATT CAG ATC3’ [EcoRI 
site underlined] for amplification using pCKB113 as the template, and the product was cloned 
between the BamHI and EcoRI sites of pET28a+ to give pCKB114. pCKB114 carried the drrA 
gene fused to an upstream sequence encoding a  hexahistidine tag, and the drrB gene fused to a 
downstream sequence encoding a myc epitope.  Further cloning was performed in order to place 
the his-drrA-drrB-myc –encoding sequence under the control of the mycobacterial hsp60 
promoter in a shuttle vector with E. coli and mycobacterial origins of replication (derived from 
pYUB12) [17] and a kanamycin resistance marker generating the plasmid pCKB115.  
Expression of proteins in E. coli- Recombinant  plasmids derived from pET28a+ were 
transformed in  E. coli BL21 (DE3). Cells were grown upto mid log phase (OD600=0.6) in Luria 
broth and induction was carried out at different temperatures with  different concentrations of 
IPTG. Recombinant plasmids derived from pBad-HisA were transformed into E. coli LMG194 
cells (Invitrogen pBAD Manual) and induced with varying concentrations of arabinose at 
different temperatures.  
Expression of proteins in Mycobacterium smegmatis mc2155-  Electroporation of  M. smegmatis 
mc2155 with the plasmid pCKB115 was performed as described by Larsen [19] Transformants 
were grown in Luria broth supplemented with 25 mg/ml kanamycin up to an A600 of 0.8 followed 
by heat shock. 
Fractionation of cells and localization of proteins- E. coli cells after induction  were suspended in 
10 mM Tris-HCl (pH 7.4), 1 mM MgCl2, 1mM phenylmethylsulphonylfluoride (PMSF), 20mg/ml 
leupeptin, 10 mg/ml pepstatin and 10 mg/ml aprotinin, and  sonicated thrice at 200 W for 15 sec. 
The unbroken cells were removed by centrifugation at 500 x g for 5 min. Inclusion bodies were 
obtained by  centrifugation  at 5000  x g for 5’ . Membranes were obtained by centrifugation at 
100,000 x g for 60 min, and the supernatant constituted the cytosolic extract. Membranes from M. 
smegmatis transformants were prepared as described by Basu et al.[20]. 
ATP binding experiment -Photolabelling of membranes was carried out with [a-32P]ATP (NEN, 
Easytides) at varying concentrations  and a specific activity of 0.25 mCi/mmol in 10 mM Tris 
HCl, pH 7.4 containing 10 mM DTT. Where indicated, doxorubicin   was added to the reaction 
mixture to a final concentration of 50mM and 100 mM and MgCl2 was added to a final 
concentration of 5 mM. The  reaction  was carried out in a volume of  25ml  in a  96-well 
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microtitre plate kept on a block of ice directly  under UV (254 nm) illumination for 30 min. 
Samples were analyzed by SDS-PAGE and autoradiography.  
Minimum inhibitory concentrations (MIC)- E. coli BL21(DE3)/pCKB114 or M. 
smegmatis/pCKB115 were induced as described above in order to express DrrA and DrrB. MICs 
were determined by the broth microdilution method according to National Committee for Clinical 
Laboratory Standards guidelines [21]. Cells were  added at a CFU of 106 per ml in microtitre 
wells (in duplicate) containing serial dilutions of different drugs. Controls without drug were also 
run. The plate was incubated at 37oC overnight (for E. coli) or 48 h (for M. smegmatis). MIC was 
defined as the lowest concentration of drug with complete absence of growth(Absorbance at 
600nm >0.05 i.e.,a value equal to visible growth).Each MIC was determined at least thrice using 
three different transformants.   
Uptake of [14C]-doxorubicin - Cells expressing DrrA and DrrB were grown up to mid-log phase, 
induced, harvested and suspended to an OD600 of 20 in 50 mM K-phosphate,  pH 7.4 containing 5 
mM MgSO4 . Uptake was initiated (in the absence or in the presence of inhibitors) by the addition 
of doxorubicin (5 mM; 10-50 mCi/mmol) . Cells were  diluted into ice-cold 10 mM K-phosphate, 
pH 7.4 containing 0.1 M LiCl, filtered on glass fibre (Whatman GF/C) filters, dried and counted 
in a liquid scintillation counter. 
Uptake of 2’,7’-bis-(2-carboxyethyl)-5(-and 6)-carboxyfluorescein acetomethoxyl ester (BCECF-
AM)- This was done  as described by Bolhuis et al. 1996 [22]. The cells were harvested and 
washed thrice with 50 mM HEPES buffer, pH 7.3 containing 25 mM K2SO4 and 5 mM  MgSO4. 
Subsequently, the cells were resuspended in the buffer to a final OD600  of 20. BCECF-AM (2mM 
stock solution in dimethyl sulphoxide) was added to the cell suspension to a final concentration of 
1 mM. BCECF fluorescence was monitored continuously  at excitation and emission wavelengths 
of 502 and 525 nm respectively, in a HITACHI (F-4500) spectrofluorimeter, equipped with a 
thermostatically-controlled (37oC), magnetically-stirred cuvette holder. 
 
RESULTS 
Expression and localization of DrrA in E. coli -DrrA was expressed in E. coli 
BL21(DE3)/pCKB105 at 30oC  at an IPTG concentration of  100 mM for 4h (Fig. 1, Panel A). 
The protein  localized primarily  in the inclusion bodies (data not shown).  
Expression of DrrB in E. coli- Attempts to express DrrB (cloned in the vector pE28a+) in E. coli 
BL21(DE3) were abortive. The expressed  protein appeared to be extremely sensitive to 
proteolysis. DrrB was also cloned in the vector pBAD-HisA (Invitrogen) under the control of the 
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araBAD promoter and expressed in E. coli LMG-194. This was done in view of the fact that the 
araBAD promoter (pBAD) of E. coli allows regulated expression facilitating optimum expression 
of protein in its properly folded form.  Briefly, transformed cells were grown up to an OD600 of 
0.6 in RM-glucose medium with 50mg/ml ampicillin  as described in the Invitrogen pBAD 
Manual. Cells were induced with 0.002 % arabinose at 30oCfor 4 h. Induced cells were pelleted 
down, subjected to three cycles of freezing and thawing, and run on SDS-polyacrylamide (12.5%) 
gels. Expressed  DrrB migrated as a polypeptide of apparent molecular mass  31 kDa (Fig. 1, 
panel B). DrrB  localized exclusively to the  membranes. However, it still remained sensitive to 
proteolytic degradation. Attempts to extract it from membranes using various detergents, were 
abortive. 
Tandem expression of DrrA and DrrB- When E. coli BL21(DE3)/pCKB102 harbouring  the  
drrAB genes was induced with 50mM IPTG, the expression of DrrA was visible on 
polyacrylamide gels, but the expression of DrrB could not be visualized. An artificial operon was 
therefore constructed to allow the simultaneous expression of DrrA and DrrB. An artificial 
ribosome-binding site was introduced upstream of the drrB gene (Fig. 1, panel D), and the drr A 
and drrB  genes were fused downstream of a hexahistidine encoding sequence and upstream of a 
myc epitope encoding sequence respectively in the vector pET28a+ to give the plasmid 
pCKB114. Induction of DrrA and DrrB was found to be optimal when carried out using   50mM 
IPTG at 30oC for 4 h. Membranes, cytosolic extracts and inclusion bodies  were prepared as 
described above. In crude cell extracts, bands corresponding to  both DrrA and DrrB were visible 
on SDS-polyacrylamide gels. Both DrrA and DrrB were present exclusively in the membranes of 
these cells (Fig. 1, panel C, lanes 1 and 2) as confirmed by Western blotting with anti-His and 
anti-myc antibodies (Fig. 1, panel C, lanes 3 and 4). E. coli transformants could be stored as 
glycerol stocks at –70oC for  several weeks without loss of expression of DrrAB. 
Expression of DrrAB in M. smegmatis – In order to evaluate the functional characteristics of the 
DrrAB efflux pump in mycobacteria, conditions were optimized for expression of both DrrA and 
DrrB under the control of the heat shock promoter, hsp60, in M. smegmatis. Heat shock was 
given at temperatures ranging from 37 to 45oC for varying periods of time (30 min to 2 h). 
Optimum expression was observed following heat shock at 42oC for 45 min.  Both components of 
the pump localized to the membranes of induced cells as judged by western blotting using anti-
His and anti-myc antibodies (Fig. 1, panel E). M. smegmatis transformants could be stored as 
glycerol stocks at –70oC for  two weeks  after which transformants showed very slow growth 
when cultured in liquid medium. 
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[a-32P] ATP binding-  UV-catalyzed binding of [a-32P]ATP to DrrA was observed when E. coli 
membranes expressing DrrA and B simultaneously were used for binding studies. The binding 
was enhanced in the presence of both doxorubicin (Dox) and daunorubicin (Dnr). It is possible  
that both these drugs induce a conformational change in DrrA favouring interaction with ATP.  
Uptake of [14C]-doxorubicin- [14C]-doxorubicin uptake was studied in  E. coli cells harbouring 
plasmid pCKB114 designed for tandem expression of DrrA and DrrB. Doxorubicin was used at a 
concentration of 5mM (which did not affect cell viability).  Doxorubicin  uptake was significantly 
lower in cells induced to express DrrAB  compared to uninduced cells suggesting that the 
tandemly expressed DrrA and B proteins were  associating to form a functional doxorubicin 
efflux pump (Fig. 3, panel A). This was further confirmed by determining doxorubicin 
accumulation after addition of reserpine ( at sublethal concentrations), an inhibitor of   ATP-
dependent efflux pumps. On addition of reserpine, doxorubicin accumulation in cells expressing 
both DrrA and B increased to levels similar to that observed in uninduced cells. DrrAB therefore 
appeared to associate to form a functional doxorubicin efflux pump. Accumulation levels in cells 
expressing DrrA or DrrB alone were similar to uninduced cells (data not shown). The uptake of 
doxorubicin   in  M. smegmatis was again found to be inhibitable by reserpine (Fig. 3, panel B), 
suggesting that the pump is functional in M. smegmatis. In E. coli and in M. smegmatis, the 
difference in accumulation in the induced and uninduced states while being statistically 
significant,  ranged between 2.5 and 3-fold. 
BCECF-AM transport-  BCECF-AM is a non-fluorescent, neutral compound which  diffuses 
across the cytoplasmic membrane. Once inside the cell, BCECF-AM is rapidly hydrolyzed by 
non-specific esterases, trapping the non-permeant hydrophilic free acid BCECF within the cell. 
BCECF accumulated after the addition of BCECF-AM to E.coli BL21(DE3)/pET28a+ or to E. 
coli BL21(DE3)/pCKB114. Intracellular accumulation was strongly reduced in the latter case 
compared to cells containing vector alone. The expression of DrrAB therefore appeared to play a 
role in decreased accumulation of BCECF, suggesting that neutral compounds may also serve as 
substrates of the Drr pump. Addition of reserpine was able to partially restore the level of 
accumulation of BCECF to that of cells expressing vector alone (Fig. 4). The likely presence of 
reserpine-insensitive pump(s) in E. coli BL21(DE3) probably accounts for  the inability of 
reserpine to fully restore BCECF accumulation. Cells expressing only DrrA or DrrB behaved in a 
manner similar to cells harbouring the vector pET28a+ or the vector pBAD-HisA alone (data not 
shown). The presence of constitutive extracellular mycobacterial  esterases made it impossible to 
study BCECF accumulation in M. smegmatis. 
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Effect of DrrAB expression on drug susceptibility-  E. coli BL21(DE3)/pCKB114 expressing 
DrrA and DrrB  simultaneously showed increased resistance to ethidium bromide, doxorubicin, 
daunorubicin, chloramphenicol and puromycin. (Table 1). Cells expressing DrrA or DrrB alone 
behaved like cells harbouring  the vector pET28a+ or the vector pBAD-HisA alone (data not 
shown).  
The DrrAB pump is likely involved in the transport of phthiocerol dimycocerosate to the cell 
surface in M. tuberculosis. In addition, another physiological role of such a pump could be to 
pump out toxic lipophilic metabolites or hydrophobic compounds which are encountered in the 
extracellular environment. To address the role of DrrAB in antibiotic resistance in mycobacteria, 
the  MICs of  M. smegmatis expressing DrrAB towards a range of clinically relevant antibiotics 
were determined. . DrrAB conferred  resistance to a broad range of clinically relevant antibiotics, 
including tetracycline, erythromycin, ethambutol, norfloxacin, streptomycin and 
chloramphenicol. This suggested a possible role that it might play in antibiotic resistance of M 
tuberculosis.  
The differences in the –fold enhancement of MICs (in the case of some drugs)  due to the 
expression of DrrAB observed between E. coli and M. smegmatis may be attributed to: (a) 
different roles of the permeability barrier, (b) roles of other efflux pumps, (c) differences in target 
sensitivities and (d) different drug-inactivating mechanisms  in  the two organisms. 
  
DISCUSSION  
The principal physiological role of the Drr proteins of M. tuberculosis appears to be in the export 
of complex lipids to the cell exterior. The role of ABC transporters in lipid transport is now being 
acknowledged widely [23]. The role of the drr operon in transport of DIM to the cell surface in 
M. tuberculosis has also been documented [15 ]. The results of drug susceptibility profiling in the 
E. coli and M. smegmatis expression systems for DrrAB developed by us suggest a role of this 
pump in resistance against  hydrophobic drugs.  The attempts to express the two proteins 
individually in E. coli, suggest that neither of the two proteins retains its integrity in the absence 
of the other protein. DrrB appeared to be exquisitely sensitive to proteolysis in the absence of 
DrrA.  The use of the artificial operon to achieve simultaneous expression of DrrA and DrrB, 
allows the demonstration of the interdependence of the two proteins.  The targeting of DrrA to the 
membranes is facilitated by the coexpression of DrrB, while the stability of DrrB in the 
membranes is facilitated by the simultaneous presence of DrrA in the membranes. In E. coli, both 
cationic hydrophobic compounds such as doxorubicin and neutral compounds such as BCECF 
appeared to be substrates of the functional DrrAB efflux pump. The expression of the pump in E. 
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coli imparted 8-fold increased resistance to ethidium bromide, a cationic substrate of ABC 
transporters. Increased adduct formation with [a-32P]ATP in the presence of doxorubicin or 
daunorubicin raised the possibility that substrate binding to the pump induces a conformational 
alteration favouring ATP binding to DrrA. This is similar to  the observation that Dox stimulates 
ATP binding to DrrA of S. peucetius [24]. Whether it does so by binding to a site in the DrrA 
protein or exerts an indirect effect after binding to DrrB is open to question. Drug-stimulated 
ATPase activity has been reported in the case of the human P-glycoprotein [25].  The 
overexpression of a functional doxorubicin efflux pump from M. tuberculosis and its inhibition 
by known inhibitors of ABC transporters such as reserpine, exemplifies the characterization of an 
ABC transporter for the first time from this globally important pathogen, and demonstrates that it 
imparts resistance to hydrophobic drugs. The use of doxorubicin accumulation to determine 
functionality of the DrrAB pump provides an assay system for biochemical characterization of 
this pump. The difference in accumulation levels between induced and uninduced cells range 
between 2.5- and 3-fold in E. coli and M. smegmatis. This suggests that only inhibitors that 
inhibit the pump almost completely are likely to be picked up without ambiguity using this assay 
system. Similarly, the effects of mutations of conserved amino acid residues are likely to be 
reflected unambiguously when such mutations inhibit the pump almost completely. Nevertheless 
the expression systems described here deserve further evaluation considering that development of 
an assay system based on the likely natural substrate DIM, appears even more technically 
challenging and elusive. The differences in MIC observed in M. smegmatis expressing DrrAB 
suggest that this pump confers resistance towards a broad range of structurally unrelated drugs in 
mycobacteria. This is like the observation that LmrA, the Lactococcus lactis counterpart of the 
human P-glycoprotein, shows broad substrate specificity [26]. The M. smegmatis assay system is 
likely to be useful in evaluating drugs of potential against mycobacteria by virtue of their ability 
to inhibit DrrAB. On the other hand, the E. coli expression system is more robust;  E. coli 
transformants being more stable than M. smegmatis transformants when stored as glycerol stocks 
at –70oC. E. coli also has the advantage of faster generation time than M. smegmatis. 
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Table 1. Drug susceptibility of cells expressing DrrAB 
                      Minimum inhibitory concentrations (MIC) 
                          of transformants (mg/ml) 
   __________________________________________________________________________ 
A.              E. coli               M. smegmatis 
Drug         uninduced   induced    uninduced           induced  ____________ 
                                     no inhibitor   +reserpine  +verapamil 
                                             (10 mg/ml)   (10 mg/ml) 
 
Ethidium bromide  20       160       3          12        6        6 
Daunorubicin     20        40        5          20        5        5 
Ethambutol      N.D.     N.D.    0.5          4        1       0.5 
Doxorubicin      20       60      20          60       25        20 
Puromycin       20        40     N.D.              N.D.      N.D.     N.D. 
Chloramphenicol     1         2       6          36       12         6 
Erythromycin     N.D.     N.D.    10          40       20        10 
Norfloxacin      N.D.     N.D.     2.5          10        5        2.5 
Streptomycin     N.D.     N.D.     1           8        4         4 
Tetracycline        N.D.     N.D.     0.25         4        1       0.25 
*N.D., not determined 
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LEGENDS TO FIGURES 
Fig. 1. Expression of the DrrA and DrrB proteins. Cells were grown and induced as described 
under Experimental Procedures. Cells were suspended in Laemmli sample buffer, run  on SDS-
polyacrylamide (12%) gels and visualized by staining with Coomassie Blue. (A) DrrA in E. coli 
BL21(DE3)/pCKB105 lanes 1 and  2  represent uninduced  and  induced cells respectively. (B) 
DrrB in E. coli LMG194/pCKB109, lanes 1, 2  3 and 4  represent uninduced cells, induced cells, 
and membranes from induced cells and uninduced cells,  respectively. (C) Membranes from 
uninduced (lane 1) and induced (lanes 2-4) E. coli BL21(DE3)/pCKB114 were run on  SDS-
polyacrylamide (12%) gels,  transferred on to nitrocellulose and either stained with Amido Black 
(lanes 1 and 2) or probed with anti-His (lane 3) or anti-myc (lane 4) antibodies. (D) Schematic 
representation of the artificial operon constructed for translational coupling and simultaneous 
expression of DrrA and DrrB. (E) Western blots of  M.smegmatis/pCKB115 membranes from 
uninduced (lanes 1 and 3) and induced (lanes 2 and 4), probed with anti-His (lanes 1 and 2) or 
anti-myc (lanes 3 and 4) antibodies.   
Fig. 2. [a-32P]ATP binding to DrrA. UV-catalyzed adduct formation between DrrA and [a-
32P]ATP was performed in membrane fractions of cells expressing DrrA and B. Adduct formation 
was catalyzed as described under Experimental procedures. Proteins were resolved on SDS-
polyacrylamide (12%) gels, followed by autoradiography. (A). Effect of Mg2+ (5 mM) and 
varying concentrations of ATP on adduct formation. (B) Effect of doxorubicin (40mM) and 
daunorubicin (40mM) on adduct formation carried out in the presence of 5 mM Mg2+ and 200 mM 
ATP.   
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Fig. 3. [14C]Doxorubicin accumulation in E. coli (panel A) and M. smegmatis (panel B) 
expressing DrrA and DrrB. Steady state accumulation levels of doxorubicin in uninduced (solid 
bars) cells were taken to be 100%. Accumulation in  uninduced and induced (shaded bars) cells in 
the absence of inhibitors have been termed as controls.  Where indicated, induced cells were 
incubated with 5 mM doxorubicin and increasing concentrations (mg/ml) of inhibitors. Data 
expressed represent the mean ± SD of three separate determinations using three different batches 
of transformants. 
Fig. 4. Uptake of BCECF by cells expressing DrrA and DrrB. BCECF-AM ( 1 mM  ) was added 
to:  E. coli BL21(DE3)/pET28a+ energized with glucose  (A) or E. coli BL21(DE3)/pCKB112 
induced with IPTG and  energized with glucose (C) or E. coli BL21(DE3)/pCKB114 induced 
with IPTG,  energized with glucose and incubated with reserpine (10  mg/ml) (B).  
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ABBREVIATIONS 
BCECF-AM . 2’,7’-bis-(2-carboxyethyl)-5(-and 6)-carboxyfluorescein acetomethoxyl ester ;  
DIM, phthiocerol dimycocerosate; IPTG, isopropyl b-D-thiogalactoside
Biochemical Journal Immediate Publication. Published on 11 Jun 2002 as manuscript BJ20020615
Copyright 2002 Biochemical Society
 19 
Biochemical Journal Immediate Publication. Published on 11 Jun 2002 as manuscript BJ20020615
Copyright 2002 Biochemical Society
 20 
 
Biochemical Journal Immediate Publication. Published on 11 Jun 2002 as manuscript BJ20020615
Copyright 2002 Biochemical Society
 21 
Biochemical Journal Immediate Publication. Published on 11 Jun 2002 as manuscript BJ20020615
Copyright 2002 Biochemical Society
 22 
 
Biochemical Journal Immediate Publication. Published on 11 Jun 2002 as manuscript BJ20020615
Copyright 2002 Biochemical Society
